Search Results - "Solingen-Ristea, Rodica Van"

Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.

Authors: Teichner, Paula Chamay, Nadine Elliot, Emilie et al.

Source: Open Forum Infectious Diseases. Jun2024, Vol. 11 Issue 6, p1-10. 10p.

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.

Authors: Smith, Graham H R Henry, W Keith Podzamczer, Daniel et al.

Source: Open Forum Infectious Diseases. Sep2021, Vol. 8 Issue 9, p1-9. 9p.

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.

Authors: Elliot, Emilie R Polli, Joseph W Patel, Parul et al.

Source: Journal of Infectious Diseases. 7/15/2024, Vol. 230 Issue 1, pe34-e42. 9p.

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.

Authors: Overton, Edgar T Richmond, Gary Rizzardini, Giuliano et al.

Source: Clinical Infectious Diseases. May2023, Vol. 76 Issue 9, p1646-1654. 9p.

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.

Authors: Teichner, Paula Cutrell, Amy D'Amico, Ronald et al.

Source: Open Forum Infectious Diseases. 2019 Supplement, Vol. 6, pS20-S20. 1p.